Alpha Tau Medical

Cancer Radiotherapy

Health Tech & Life Sciences
Public on NASDAQ on Mar 2022

Company Overview

Snapshot

Founded in January 2016 by Prof. Itzhak Kelson and Prof. Yona Keisari, Alpha Tau Medical operates with 51–200 employees. The company has raised $201.9M across 7 funding rounds from 10 investors. In March 2022, Alpha Tau Medical went public on NASDAQ.

Business overview

Alpha Tau Medical is a medical device company specializing in the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for treating solid cancers. This technology, developed at Tel Aviv University, utilizes alpha-emitting atoms directly inserted into tumors to deliver a high-energy dose, enabling focal alpha-radiation treatment that spares surrounding healthy tissue. The company serves the oncology and healthcare sectors, focusing on therapeutic devices and cancer therapy.

Strategic signal

In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, a critical step towards FDA approval of Alpha DaRT for recurrent cutaneous squamous cell carcinoma. This milestone signals significant progress in bringing its innovative radiotherapy to market, validating the company's clinical development strategy and potentially expanding treatment options for patients with this challenging cancer.

Company Intelligence Q&A

What is Alpha Tau Medical's primary therapeutic focus?
Alpha Tau Medical focuses on developing and commercializing its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers.
When did Alpha Tau Medical go public?
Alpha Tau Medical went public on NASDAQ in March 2022.
What significant clinical milestone did Alpha Tau Medical achieve in May 2026?
In May 2026, Alpha Tau Medical completed patient enrollment in its U.S. pivotal skin cancer study, advancing towards FDA approval of Alpha DaRT for recurrent cutaneous squamous cell carcinoma.
Which investor led a PIPE funding round for Alpha Tau Medical in April 2025?
In April 2025, Oramed Pharmaceuticals led a PIPE funding round for Alpha Tau Medical.
What was a key development for Alpha Tau Medical's manufacturing capabilities in October 2025?
In October 2025, Alpha Tau Medical announced the receipt of a Radioactive Material License for its New Hampshire manufacturing facility, moving towards commercial readiness.

External links